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Abstract: Introduction: Between 1993 and 2000 four acetylcholinesterase inhibitors were marketed as a symptomatic 
treatment for Alzheimer’s disease (AD), as well as memantine in 2003. Current research is focused on finding drugs that 
favorably modify the course of the disease. However, their entrance into the market does not seem to be imminent.  
Research Development: The aim of AD research is to find substances that inhibit certain elements of the AD pathogenic 
chain (beta- and gamma-secretase inhibitors, alpha-secretase stimulants, beta-amyloid aggregability reducers or disaggre-
gation and elimination inductors, as well as tau-hyperphosphorylation, glutamate excitotoxicity, oxidative stress and mito-
chondrial damage reducers, among other action mechanisms). Demonstrating a disease’s retarding effect demands longer 
trials than those necessary to ascertain symptomatic improvement. Besides, a high number of patients (thousands of them) 
is necessary, all of which turns out to be difficult and costly. Furthermore, it would be necessary to count on diagnosis and 
progression markers in the disease’s pre-clinical stage, markers for specific phenotypes, as well as high-selectivity mole-
cules acting only where necessary. In order to compensate these difficulties, drugs acting on several defects of the patho-
genic chain or showing both symptomatic and neuroprotective action simultaneously are being researched.  
Conclusions: There are multiple molecules used in research to modify AD progression. Although it turns out to be diffi-
cult to obtain drugs with sufficient efficacy so that their marketing is approved, if they were achieved they would lead to a 
reduction of AD prevalence.  
Keywords: Acetylcholinesterase inhibitors, Alzheimer’s disease, antioxidants, cell therapy, disease-modifying drugs, immuno-
therapy, memantine, secretase inhibitors. 
INTRODUCTION  
  From 1906, when the first case of Alzheimer’s disease 
(AD) was described, until 1993, when tacrine was marketed, 
there were no specific treatments for this disorder. Between 
1996 and 2000, new anticholinesterases entered the market 
and so did memantine in 2003. Currently, the marketing of 
new formulas for symptomatic treatment does not seem to be 
imminent and the interest of research is focused on finding 
products aimed at modifying the course of the disease. Un-
fortunately, years and years are going by and these drugs do 
not reach the market. This paper analyses synoptically the 
state of affairs of this research and the reasons hindering 
such an expected step in the history of AD.  
SYMPTOMATIC TREATMENT  
  Since the 70s it is known that brain cholinergic defi-
ciency is noticeable and early in AD, taking part in the gene-
sis of certain manifestations such as hypomnesia. Tacrine 
(the first AD symptomatic treatment) is an acetylcho-
linesterase inhibitor (ACEI) which boosts brain cholinergic 
activity. It requires four doses a day and some patients do not 
have enough enzymatic resources in their liver to detoxify 
the products of its metabolism. New prescriptions of tacrine 
were interrupted when donepezil was approved in 1996,   
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since the latter is well-tolerated and suitable for a daily dose. 
Subsequently, rivastigmine (1998) and galantamine (2000) 
were approved, two anticholinesterases which inhibit acetyl-
cholinesterase to a lower extent than donepezil does. Rivas-
tigmine compensates it through the simultaneous inhibition 
of butyrylcholinesterase and galantamine by exerting allos-
teric modulation of presynaptic muscarinic receptors, thus 
increasing acetylcholine secretion at the synaptic space. In 
clinical trials with ACEI against placebo, significant im-
provement was observed in cognition, behavior, functional 
autonomy and clinical global impression in patients ranging 
from incipient to moderately advanced AD [1]. A meta-
analysis of 10 trials shows that, from 6 months onwards, 
patients treated with placebo worsen an average of 2.16 
points on the cognitive scale ADASCog (70 points), while 
those treated with an ACEI in optimum doses undergo an 
average improvement of 0.27 points (average difference = 
2.43 points) [1]. The difference among ACEIs’ effect does 
not exceed one point and thus meta-analyses do not find any 
significant difference regarding effectiveness on cognition 
among the three ACEI in use [1-3].  
  There exists a constant excess of glutamate in the synap-
tic clefts in diseased cells, which determines an excessive 
entrance of Ca
++ into the cell through the existing channels in 
glutamate NMDA receptors. That’s why the post-synaptic 
cell is permanently depolarized, thus not being functional. 
Memantine, a NMDA receptor antagonist, prevents such 
continuous depolarization and keeps the usefulness of post-
synaptic cells. Due to its voltage-dependent action mecha-28     The Open Neurology Journal, 2009, Volume 3  Alfredo Robles 
nism, low-moderate affinity towards NMDA receptors and a 
fast channel-blocking/unblocking kinetics, when a stimulus 
from the pre-synaptic cell arrives, it allows the opening of 
the Ca
++ channels and a normal action potential takes place 
in the post-synaptic neuron [4]. Thus, a population of neu-
rons which had already lost their activity is able to prolong it 
due to the action of memantine. This explains its positive 
effect on cognition and functional autonomy [5, 6] as well as 
on behavior [7-9], allowing it to be marketed in 2003 for the 
treatment of patients in moderately advanced and advanced 
stages (with scores in the Folstein mini-mental state exami-
nation —MMSE— below 15). A meta-analysis of studies 
including patients with less advanced AD developed in 2007 
allowed to extend its use to moderate AD (MMSE scores 
ranging between 15 and 19) [5, 10].  
  Although ACEI are more effective during initial stages of 
dementia and memantine in its advanced stages, both treat-
ments are effective throughout the whole evolution of the 
Alzheimer’s disease. In fact, the US Food and Drug Admini-
stration (FDA) approved in 2007 the use of donepezil in ad-
vanced AD and, when experimentation with memantine in 
incipient AD prolongs, the positive effect obtained in the 
trials carried out so far could be verified [6, 11-13].  
ADVANCES IN SYMPTOMATIC TREATMENT  
  Immediate marketing of new symptomatic treatments for 
AD does not seem foreseeable. However, the use of the 
ACEI available might be extended to the advanced stages of 
the disorder, following the path of donepezil. The appear-
ance of new formats in 2007 and 2008 (galantamine in sus-
tained-release capsules, donepezil in flas and rivastigmine 
patches) has increased the treatment’s tolerability, comfort 
and compliance. Memantine shows high tolerability and ef-
fectiveness in daily dose [14, 15], so that such a dosage has 
been accepted since 2008.  
  Some of the drugs researched to modify the course of AD 
have symptomatic effects (Table 1). If any of them were 
used as a progression modifier, it would also increase at the 
same time the arsenal of symptomatic treatments. It may also 
Table 1.  Drugs with Symptomatic and Neuroprotective Action 
 
 Action 
Dimebolin  ACEI + inhibitor of calcium L-channels and NMDA receptors 
Huperzine A  ACEI + antioxidant and stimulant of muscarinic and nerve growth factor receptors  
Phenserine ACEI  +  sAPP- and A reducer 
Memoquin  ACEI + I-BACE, antioxidant and -hyperphosphorylation reducer 
Bis-tacrine  tacrine dimmer. ACEI + I-BACE-1 and anti-NMDA 
Lipocrine  tacrine (ACEI) and lipoic acid (antioxidant) hybrid 
Tacrine-melatonin hybrids  ACEI + antioxidants 
Ladostigil  rivastigmine (ACEI) and rasagiline (antioxidant) hybrid 
Memantine  anti-NMDA + PP-2A stimulant (it decreases neurofibrillary degeneration), oxidative stress and activated microglia reducer  
sAPP-:  variant of the soluble APP. 
Table  2.  Genes in which Determining Mutations and Susceptibility Polymorphisms (Associated to a Higher or Lower Risk)   
Related to AD have been Found 
 
Gene  Protein  Chromosome  Known FAD Pathogenic Mutations* 
PSEN2  presenilin 2  1  14 
PSEN1  presenilin 1  14  173 
APP  A precursor protein  21  30 
     SA**  OR
a  OR
b 
APOE  apolipoprotein E  19  4 vs 3  3.68  3.81 
CHRNB2  2 subunit of the neuronal nicotinic receptor  1  T vs G  0.67  0.69 
GAB2  GRB2 associated binding protein 2  11  T vs G  0.84  0.81 
CH25H  cholesterol 25-hydroxylase   10  T vs C  1.44  1.38 
SORL1  Sortilin-related receptor   11  G vs C  0.9  0.7 
CALHM1  calcium homeostasis modulator 1   10  T vs C  1.42  1.42 
CST3  cystatin C  20  C vs G  1.23  1.28 
ACE  angiotensin I converting enzyme 1  17  C vs T  0.83  0.79 
PGBD1  piggyBac transposable element derived 1  6  A vs G  1.25  1.25 
MAPT/STH  microtubule-associated protein /saitohin   17  T vs C  1.24  1.24 
*: Taken from http://www.molgen.ua.ac.be/ADMutations/ in November 2008.  
**: Among the numerous genes in which susceptibility polymorphisms to develop sporadic AD have been found, we have pointed out those 10 genes which, up to now, have shown 
a greater degree of association (taken from http://www.alzforum.org/res/com/gen/alzgene/ in November 2008).  
FAD: familial Alzheimer's disease. OR
a, OR
b: Odds ratio obtained from the meta-analysis of all available studies (a) and studies on Caucasians (b). SA: susceptibility alleles. New Treatments for Alzheimer Disease  The Open Neurology Journal, 2009, Volume 3    29 
be that the symptomatic effect achieved will be precisely that 
which would allow them to enter the market.  
TREATMENTS THAT MODIFY THE EVOLUTION 
OF THE DISEASE  
  The knowledge of the etiopathogeny of AD is gradually 
increasing. A large number of mutations that lead to the de-
velopment of familial AD, and numerous susceptibility po-
lymorphisms that increase the risk of suffering sporadic AD, 
have already been identified (Table 2). An early and essen-
tial phenomenon is the formation of beta-amyloid (A) and 
its aggregation, followed by a sequence of pathological 
events that lead to cell dysfunction and, subsequently, to 
premature cell death (Table 3). Certain susceptible brain 
regions are affected first, and the topographical expansion 
follows a regular chronology in typical cases [16, 17]. Re-
searchers try to intervene in the steps of this pathogenic 
chain in order to slow down its morbid process. However, it 
is known that the administration of a neuroprotective drug 
does not necessarily involve any modification in the evolu-
tion of the disease and, when such a modification is 
achieved, it frequently does not take place to a significant 
degree.  
  The symptomatic treatment acts by reducing a neuro- 
chemical imbalance which gives rise to particular symptoms  
(Fig. 1). When the treatment is withdrawn, its beneficial ef- 
fect disappears (Fig. 2.4). When a drug improves the condi- 
tion of AD patients, it is sometimes doubtful if the improve- 
ment is due to a symptomatic action or to a modification in  
the course of the disease, or if both effects act together [18].  
There are some aspects of the evolution that are useful in  
checking if the course of the disease is changing [18-21]:  
a)  If a drug extends the time that elapses until a devel-
opmental moment is reached (a further stage of de-
mentia, the need to be institutionalized, death, etc.), 
we may attribute evolution-modifying properties to it, 
once we have excluded the intervention of any other 
influent factor.  
b)  A slower progression than expected also suggests that 
the drug is not merely symptomatic. In an evolution-
ary diagram, a progressively wider difference be-
tween the functional capacity of medicated and un-
medicated patients would be observed (diverging 
lines) (Fig. 3.4 and 3.5). If progression speed is de-
ducted from the slope of the evolution line, it is then 
necessary to compare the evolution of patients in 
equivalent clinical stages.  
c)  When a solely symptomatic drug is stopped, the evo-
lution curve will quickly overlap that of the untreated 
patients (Fig. 2.4). The improvement (or less impair-
ment) achieved by an evolution-modifier drug does 
not disappear, or it does only partially, after being 
stopped (Fig. 2.5).  
d)  Patients receiving a symptomatic treatment, once the 
necessary time to reach its maximum effect has gone 
by, should be comparable to other patients who are in 
the same stage of the disease and began the same 
treatment before. If the former are in a worse situation 
than the latter, it should then be inferred that the 
treatment modifies the course of the disease and, for 
such a reason, its early onset has long-lasting accu-
mulative effects (Fig. 4). 
e)  Paraclinical parameters acting as progression markers 
should show progression slowness in patients receiv-
ing drugs which modify the course of the disease. 
Magnetic resonance image of the hippocampal re-
gion, positron emission tomography (PET) with 
markers of amyloid plaques, or modifications of A42 
and tau or phospho-tau in cerebrospinal fluid are 
some useful elements for this purpose, although their 
validity has not been fully proven yet [20, 22]. Tests 
based on cerebral metabolism or perfusion (FDG-PET 
or HMPAO-SPECT, for instance) do not have the 
same validity, since some symptomatic treatments 
can modify them [18].  
I. Neuroprotective Action of Drugs Approved for the 
Symptomatic Treatment of AD  
  Several evidences point out that ACEI and memantine 
have a modifying effect on the evolution of AD. O. Lopez et 
al. have observed a higher interval until the patients adminis-
tered ACEI are admitted to a nursing home [23] and, if me-
mantine is added, such an interval is significantly higher and, 
moreover, survival time is also extended (paper by OL Lo-
pez et al. read at the 60
th Annual Meeting of the American 
Academy of Neurology, April 2008).  
•  Donepezil acts on the deep region of the acetylcho-
linesterase, where the acetylcholine is hydrolyzed, 
and on the surface area that interacts with A and fa-
cilitates its aggregation. Its double nature gives it, 
Table 3.  Some of the Pathological Events that Take Place in AD 
 
•  Abnormal hydrolysis of APP (-secretase and -secretase)  A production (A40, A42) 
•  Fibrillogenesis: polymerization and formation of A oligomers  
•  Aggregation  final formation of neuritic plaques 
•  Neurofibrillary degeneration: hyperphosphorylation of -protein  neurofibrillary tangles 
•  Glutamate excess in synapses  excitotoxicity 
•  Activation of microglia and presence of inflammatory proteins 
•  Imbalance in intracellular ion homeostasis (calcium, copper, iron, zinc) 
•  Oxidative stress  free radicals toxicity 
•  Alterations of the mitochondrial membrane  failure of the cellular energetic system 30     The Open Neurology Journal, 2009, Volume 3  Alfredo Robles 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Virtual graph (*) of the possible effects of a symptomatic treatment. *: In reality, the natural evolution of impairment is not lineal 
and varies according to the stage of the disease; however, the lineal diagram facilitates the conceptual understanding of the action of the 
drugs. 1: Cognitive decline related to ageing. 2: Cognitive and functional loss due to an untreated progressive disease. 3: The optimum effect 
of a solely symptomatic treatment is maintained throughout. 4: Symptomatic treatment may produce a transitory beneficial action (4a) or a 
long-lasting benefit but to a progressively lower degree (4b).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Virtual graph (*) of the possible effects of suspending a treatment with symptomatic effect. *: In reality, the natural evolution of 
impairment is not lineal and varies according to the stage of the disease; however, the lineal diagram facilitates the conceptual understanding 
of the action of the drugs.  
1: Cognitive decline related to ageing. 2: Cognitive and functional loss due to an untreated progressive disease. 3: Improvement produced by 
treatment. 4: If a treatment is only symptomatic, its action is lost when it is suspended and the patient follows the evolution of untreated pa-
tients. 5: If the treatment, apart from being symptomatic, also modifies the course of the disease, its symptomatic action is lost when it is sus-
pended, but the modification already achieved is held and the patient follows a progression line that does not overlap that of untreated pa-
tients.  
  apart from its symptomatic effect, a protective action 
against A toxicity [24]. Other effects of donepezil, 
such as the stimulation of -7 nicotinic receptors 
(which induces overexpression of the antiapoptotic 
bcl-2 protein) [25, 26] or the activation of -1 recep-
tors (which reduces lipid peroxidation in hippocampal 
regions) [27], contribute to its potential neuroprotec-
tion. These effects may explain that hippocampal at-
rophy is slower in patients treated with donepezil [28, 
29]. In a 3-year follow-up of two groups of patients 
(some treated with donepezil the whole time and oth-
ers only during the last two years), patients treated 
with the drug since the beginning of the project re-
tained better cognitive function at the end of the 3-
year period (according to MMSE) [30]. The cumula-
tive effect after a longer drug exposure represents a 
possible evolutionary modification (Fig. 4).  
•  The dual action of rivastigmine consists of inhibiting 
the hydrolysis of acetylcholine by acetylcho-
linesterase and butyrylcholinesterase. Since butyryl-
cholinesterase has greater impact on the formation of 
neuritic plaques than acetylcholinesterase [31], its in-
hibition may contribute to the lower cortical tem-
poroparietal atrophy observed in patients treated with 
rivastigmine [32]. In a 5-year follow-up of patients 
treated with rivastigmine, MMSE scores show an in-
creasing difference from the expected scores of un-
treated individuals [33] (model 5b in Fig. 3). The out-
come should be interpreted cautiously due to the high 
number of patients lost during the follow-up period 
(basal sample: 1998, after 5 years: 83). In another 
study it was observed the evolution of patients who 
gave up the treatment prematurely, using three dou-
ble-blind trials of rivastigmine against placebo; at the 
time
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Fig. (3). Virtual graph (*) of the possible effects of a treatment that modifies the evolution of the disease. *: In reality, the natural evolution of 
impairment is not lineal and varies according to the stage of the disease; however, the lineal diagram facilitates the conceptual understanding 
of the action of the drugs. 1: Cognitive decline related to ageing. 2: Cognitive and functional loss due to an untreated progressive disease. 3: 
Effect of a curative treatment (reversible disease). 4: Action of a treatment that modifies impairment progression speed, either by recovering 
the physiological slope (optimum situation, 4a) or by reducing progression speed (4b). 5: A treatment may have both symptomatic and modi-
fying effects on the evolution of the disease, so that, after achieving an initial symptomatic improvement, the patient shows a diverging pro-
gression line in comparison to that of untreated patients, regaining (5a) or not (5b) the physiological slope (1). 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Virtual graph (*) of the possible effects of a symptomatic treatment. *: In reality, the natural evolution of impairment is not lineal 
and varies according to the stage of the disease; however, the lineal diagram facilitates the conceptual understanding of the action of the 
drugs. 1: Cognitive decline related to ageing. 2: Cognitive and functional loss due to an untreated progressive disease. 3a: If a symptomatic 
treatment starts late, the improvement catches that of patients who began treatment earlier. 3b: If the treatment also modifies the course of the 
disease, its late onset does not allow reaching the benefit obtained with an earlier onset.  
  end of the 26
th week, those patients who had taken 
rivastigmine in any previous period showed superior 
cognitive performance (ADAScog) than those of the 
placebo group [34]. This outcome, according to the 
graph in Fig. (2), points out that rivastigmine modi-
fies the course of the disease.  
•  The stimulation of -7 nicotinic receptors by galan-
tamine enhances the expression of the antiapoptotic 
bcl-2 protein and has protective effects against gluta-
mate excitotoxicity, stimulated by A [25, 26, 35, 
36]. In a 36-month follow-up of patients from two 
double-blind trials with galantamine against placebo 
of 6 and 3 months of duration, the scores on the cog-
nitive scale ADAScog-11, which are always favor-
able to galantamine-treated patients, follow a diverg-
ing evolution in relation to the scores expected for un-
treated patients [37] (model 5b in Fig. 3).  
•  In many pathological states of the nervous system, 
AD among them, excitotoxicity contributes to func-
tional and structural damage. In these situations, me-
mantine experimentally shows a protective effect. 
This protective effect is reinforced by its ability to re-
duce the action of the activated microglia [38] and 
because it stimulates protein phosphatase 2A, thus re-
ducing tau phosphorylation [39, 40]. After a 28-week 
double-blind trial of memantine against placebo, a 24-
week open study was carried out. Patients treated 
with the drug continued with medication and those 
receiving placebo changed to memantine. In the end, 
the patients treated since the 29
th week, in spite of 
having improved, did not reach the same beneficial 
situation regarding cognition and functional auton-
omy as those patients who had received memantine 
since the first day of the double-blind trial. The fact 
that no overlap took place between the curves may 
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point out that memantine exerts a modifying effect on 
the evolution of AD [41] (see Fig. 4).  
•  Patients with probable AD treated with combination 
therapy (ACEI plus memantine) showed significantly 
lower mean annualized rates of deterioration in func-
tional capacity when compared to patients who re-
ceived ACEI alone or no treatment [42].  
II. Drugs Under Research for Modifying the Evolution of 
AD  
II.A. Drugs to Reduce A Production  
 Insoluble  A is formed because -secretases (presenilins) 
and -secretases (BACE --site APP cleaving enzyme-) cut 
the transmembrane amyloid precursor protein (APP), releas-
ing this intermediate fragment, instead of being done by  
and  secretases, which release the soluble fragment APPs- 
(Fig. 5). In the last few years, the strategy of inhibiting - or 
-secretase has given a hint of hope in the treatment of AD. 
Most of -secretase inhibitors also inhibit the action of this 
enzyme on the notch protein and other protein substrates that 
take part in cell differentiation processes and therefore are 
not well tolerated (they produce alterations in thymus, intes-
tine and spleen in experimental mice) [43-45]. For this rea-
son, allosteric modulators or selective inhibitors of the -
secretase which acts on the APP are currently being synthe-
sized [45-47]. The -secretase inhibitor LY450139  has al-
ready started a phase-III trial. In the phase-II trial a tendency 
towards cognitive improvement and lower A40  levels in 
blood and cerebrospinal fluid took place against placebo; 
however, no significant differences were reached [47]. The 
inhibitor may also cause eosinophilia and diarrhea and, in 
one case, death occurred after a digestive hemorrhage due to 
Barrett’s esophageal ulcer developed during the treatment 
[47]. Imatinib mesylate (antineoplastic) has shown an inhib-
iting action of -secretase without altering the notch sub-
strate, so that its experimentation in AD has been suggested 
[48]. Several experts think that the action on -secretase 
would be better tolerated, having tested BACE-1 inhibitors 
(I-BACE1) [49] and antibodies against the BACE cleavage 
site of the APP [50]. The GSK188909  I-BACE1, for in-
stance, reduces A load in transgenic mice [51], and CTS-
21166 showed good tolerability and plasmatic reduction of 
A in a phase I trial with healthy people. Successive genera-
tions of I-BACE have gradually obtained structures of low 
molecular weight and high inhibiting capacity for their pos-
sible use in clinical practice [52-60]. Apart from APP, 
BACE1 also hydrolyzes sialyltransferase ST6Gall (in the 
Golgi apparatus) and neuroregulin-1, which takes part in 
myelination processes occurring mainly after birth. Encour-
aging results have been obtained in BACE1 knockout mice, 
pointing out that the use of I-BACE in adults might not have 
negative repercussion [61, 62]. It is foreseeable that broad 
clinical trials with human patients will be undertaken soon. 
Among the multifunctional molecules under research, we 
can mention Memoquin which, apart from being I-BACE1, 
has antioxidant properties, is an ACEI and reduces A ag-
gregation and tau-hyperphos-phorylation [63].  
  Instead of inhibiting - or -secretases, there is the possi-
bility of stimulating the pathway of the -secretase. Retinoic 
acid, final product of the metabolic cascade of vitamin  A, 
modulates biological processes of proliferation, differentia-
tion and apoptosis, stimulates the activity of -secretase 
ADAM-10, protects from A toxicity and is reduced in AD 
[64, 65]. Therefore, retinoic acid analogs such as fenretinide 
[65] or activators of its PAC1 receptor, such as the neu-
ropeptide PACAP (pituitary adenylate cyclase-activating 
polypeptide) [66], constitute research elements to slow down 
the progression of AD. Among the multifunctional drugs 
which stimulate the non-amyloidogenic pathway of the -
secretase, statins and ladostigil can be included and shall be 
commented on later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Transmembrane amyloid precursor protein (APP). In normal conditions, - and -secretase act on it, thus producing the non-toxic 
fragments sAPP- and P3. In AD - and -secretase take part, releasing a less soluble fragment (A) that is subsequently polymerized and 
forms insoluble deposits. This phenomenon is decisive for the disease’s pathogeny. 
a a a a-secretase
b b b b-secretase
extracellular
cytoplasm
COOH NH2 
g g g g-secretase
membrane
g g g g-secretase
+
sAPP-a a a a P3
b b b b-amyloid (b b b bA40, b b b bA42) +
APPs-b b b b
Beta amiloide
 New Treatments for Alzheimer Disease  The Open Neurology Journal, 2009, Volume 3    33 
  Some non-steroidal anti-inflammatory drugs (NSAID) 
such as ibuprofen, indomethacin, sulindac, diclofenac (and 
not others such as acetylsalicylic acid, naproxen, celecoxib 
and rofecoxib) have shown regulating effects on A42 pro-
duction. The mechanism for this action seems to be varied 
[67], but it mainly consists of the allosteric modulation of the 
-secretase that hydrolyzes the APP, without acting on notch 
or other substrates [68, 69]. Up to this point, no randomized 
prospective trials obtaining a significant favorable modifica-
tion in the evolution of AD through NSAID treatment have 
been published. Glucocorticoids and celecoxib produce an 
amyloidogenic effect in some cases, so that it is not probable 
that their research in AD will continue [70-72]. In a broad 
epidemiological study a reduction of the risk of AD in indi-
viduals with the Apo E-4 allele who have been treated with 
NSAID was observed, but there were no differences accord-
ing to the fact that the NSAID received was or was not a 
A42-reducer [73-75]. On the other hand, knowing the side 
effects of NSAID (especially gastrointestinal effects), it 
should be proven that, after long-term administration, the 
potential modifying effect of AD is not cut short by serious 
complications. One of the -secretase modulating NSAID 
without action on notch is flurbiprofen. In the phase-II trial it 
was observed that in the subset of patients with incipient AD 
(MMSE = 20-26) and high dose of the drug (800 mg bid) 
significant improvement took place in functional autonomy 
and a positive tendency was also observed in cognition [76]. 
In the phase-III study, however, flurbiprofen failed to im-
prove cognitive functioning or autonomy in daily activities.  
 Cholesterol  increases  A-production from APP and, in 
turn, such increase reduces cholesterol synthesis. Statins 
inhibit lipidation of -secretases and through the isoprenyla-
tion of GTPase, which takes part in secretases assembly to 
the APP, reduce A-production [77, 78]. For this purpose, it 
is possible that the statins which cross the blood-brain barrier 
(simvastatin, lovastatin) are more effective than some others 
such as pravastatin or atorvastatin [79, 80]. They also have 
anti-inflammatory effects [81] and some of them, such as 
lovastatin, produce a glycogen-synthase-kinase 3 (GSK-3) 
inhibitory effect [82], through which hyperphosphorylated 
tau protein is reduced and, in fact, less neurofibrillary tangles 
have been reported in patients who have previously taken 
statins [83]. The results from epidemiological studies and 
clinical trials regarding the risk to develop AD or modifica-
tion of its evolution differ. Therefore, further evidence is 
needed before statins can be used as protectors against AD 
[84, 85]. The lipid-lowering drug fenofibrate, unlike statins, 
has an amyloidogenic effect similar to that of cholesterol 
[71, 72].  
  Apart from their sexual function, gonadal steroids exert 
other functions. Estrogens facilitate APP processing through 
the non-amyloidogenic pathway, reduce tau-
hyperphosphorylation and oxidative stress, and exert a tro-
phic stimulus on cholinergic neurons and other brain cells 
important in AD [86-91]. Epidemiological studies have ob-
served lower incidence of AD in women who have received 
treatment with estrogens [92] and lower atrophy in hippo-
campal regions [93], although observational studies with 
negative results can also be found [94-96]. Among these, 
particular emphasis needs to be given to the Women’s Health 
Initiative Memory (WHIMS) [94], a randomized dou-
ble-blind study which followed up (through an average of 4 
years) 4532 nondemented postmenopausal women older than 
64 years, who underwent treatment with conjugated equine 
estrogen and medroxyprogesterone (n=2229) or placebo 
(n=2303). Out of the 61 women who developed dementia, 40 
(66 %) belonged to the group of active treatment and 21 (34 
%) to the placebo group, which means a hazard ratio for 
probable dementia of 2.05, 45 vs 22 per 10000 person-years 
(p = 0.01). Participants came from a broader study (Women’s 
Health Initiative –WHI-) which was suspended in 2002 due 
to the incidence of adverse events. Discrepancy in the results 
of the studies is due to multiple reasons, although the main 
reason might be that estrogens slow the progression of AD 
only if they act over a prolonged period of time in an early 
pre-clinical stage, when there is still no significant A accu-
mulation. In fact, some researchers have observed that the 
administration of oestradiol to rats when A42 has already 
been accumulated exacerbates neurodegeneration [97], and 
in short-term treatment [92] or in treatment of demented 
women [98] it no longer produces beneficial effects. In prac-
tice, we cannot prescribe this treatment in pre-clinical stages, 
due to the fact that we do not know markers for this stage. 
Besides, we should make use of a treatment whose long-term 
tolerability profile does not involve a high risk/benefit index. 
Emerging in this search for alternative drugs is the use of 
leuprorelin. AD patients show higher serum and brain levels 
of luteinizing hormone (LH), which facilitates APP process-
ing through the amyloidogenic pathway [99]. Leuprorelin, 
analogous to the gonadotropin-releasing hormone (GnRH or 
LHRH), reduces LH and, in transgenic mice, gives rise to 
lower A-production and cognitive improvement [100]. In 
September 2005 a phase-III trial began, whose results have 
not been published yet.  
 Phenserine is an ACEI that reduces APPs- and A pro-
duction [101] (see Fig. 5). In a preliminary study with 20 
patients, cognitive and cortical activity improvement (PET) 
was observed [102]. However, in two phase-III trials no sig-
nificant cognitive benefit was obtained. In a post-hoc analy-
sis of the three existing phase-III studies, cognitive im-
provement was observed in patients who received higher 
doses (15 mg/day) for more than 12 months, but no signifi-
cant difference was reached against placebo regarding clini-
cal global impression.  
 Cerebrolysine is a nootropic agent which reduces apopto-
sis and facilitates neurogenesis within the hippocampal re-
gion in transgenic mice [103]. Through a kinase-inhibiting 
effect (on GSK-3 and cdk5) it reduces phosphorylated APP, 
that gives rise to lower A-production [104]. A meta-
analysis of trials carried out so far points out that intravenous 
infusion 5 days a week for 4 weeks improves clinical global 
impression, although its effect on cognition and functional 
autonomy varies; in some studies it is no different than that 
obtained with placebo [105].  
II.B. Drugs to Reduce A Aggregation  
  There exist some synthetic peptides (beta-sheet breakers) 
—for instance, A16-22m, iA5, iAb5p, iAb5p-A1, PAB-
3631-PI, SEN-304— that attempt to prevent and undo the -
folding which takes place in many A-fragments in order to 
reduce its aggregability and inhibit fibrillogenesis [106, 
107]. Another strategy is the treatment with monoclonal an-
tibodies aimed at the N-terminal region of A involved in 
fibrils precipitation; it obtains fibrillar disaggregation, giving 34     The Open Neurology Journal, 2009, Volume 3  Alfredo Robles 
back solubility to the peptide and eliminating its toxicity 
[108]. All these proceedings still have not reached advanced 
stages in human experimentation.  
 Tramiprosate (Alzhemed
®) is analogous to glycosamino-
glycans which, through their joint to A, hinders its aggrega-
tion. Unfortunately, in the last phase-III trial no significant 
clinical efficacy was reported and some researchers noticed 
that it may increase tau-aggregation [109]. Lipocrine, a hy-
brid compound of tacrine and lipoic acid, blocks the catalytic 
binding site of acetylcholinesterase and A, giving rise to a 
reduction of A aggregability as well as having antioxidant 
properties like the lipoic acid [110]. Colostrinin, derived 
from calostrum, solubilizes A-fibres and reduces its polym-
erization, besides having antioxidant properties. In studies 
against placebo, it has been observed that it leads to certain 
cognitive and functional stabilization [111]. Curcumin, a 
component of culinary curry, crosses the blood-brain barrier 
and hinders A aggregation; it is also disaggregating and has 
anti-inflammatory and antioxidant properties [112]. In a 
double-blind placebo-controlled trial with 34 patients, no 
significant clinical differences were observed and A40 se-
rum levels did not vary either [113].  
  Some metals take part in intracellular physiological oxi-
doreductive activity. Their interaction with A has various 
effects. For instance, their bind to Cu
++ (and Fe
+++ to a lesser 
extent) facilitates the formation of toxic oligomers and the 
increase of oxidative activity and formation of free radicals, 
while the presence of Zn
++ displaces Cu
++ and exerts a pro-
tective effect [114]. Therapeutic strategies try to modulate 
the presence of these metals in the brain in order to reduce 
oxidative activity, or try to eliminate free radicals already 
formed by administering antioxidants. A zinc supplement in 
diet has been suggested, but experimentation points to its 
inadvisability [115]. Treatment with metal-chelating agents 
seems to be more plausible. Among the latter, clioquinol 
(PBT-1) did not obtain sufficiently positive result in the trial 
[116] and may produce visual alterations. PBT-2 is currently 
in phase-II of experimentation. It seeks to inhibit the forma-
tion of A-oligomers and disaggregate amyloid plaques 
through promoting normal copper and zinc brain homeosta-
sis.  
  A phase-II trial with AZD-103 (scyllo-inositol, scyllo-
cyclohexanehexol), which reduces A aggregation and neu-
tralizes oligomers, has already begun. NAP (also known as 
AL-108), administered intranasally, has also reached 
phase-II in research as an octapeptide with A-antiaggregant 
and microtubule stabilizer properties. Memoquin has been 
mentioned in Section II.A as a multifunctional compound 
that reduces the A aggregability promoted by acetylcho-
linesterase [63].  
II.C. Drugs to Stimulate A Elimination  
  A technique to eliminate A is immunotherapy, which 
may be active (A is administered to stimulate the produc-
tion of antibodies) or passive (anti-A antibodies are admin-
istered). In the first case we find AN1792, whose trial in hu-
mans was suspended due to the appearance of encephalitis. 
In the brain of autopsied patients who generated antibodies, 
lower than expected A density was observed, apart from 
activated microglia and persistence of neurofibrillary tangles 
[117]. Clinically, no significant improvement against pla-
cebo was obtained [118] and greater loss of brain and hippo-
campal volume was observed through magnetic resonance 
[119]. The same dementia-progression rate was observed in 
patients showing A reduction, perhaps because neuritic 
plaques are the final product of a neurotoxic process whose 
greatest responsibility may be attributed to amyloid oli-
gomers, whose formation precedes plaque formation. On the 
other hand, a faster rate of progression was observed in pa-
tients with no amyloid reduction than in untreated patients, 
which adds fear to the use of this therapeutic technique. 
However, such line is still being researched; ACC 001 and 
CAD-106 (in phases II and I, respectively) are two formula 
of active immunotherapy that attempt to act without causing 
brain defensive reactions. Among monoclonal anti-A anti-
bodies we find AAB 001 (bapineuzumab). A study refers 
brain micro-hemorrhages in patients who underwent passive 
immunotherapy, so that further attention should be drawn to 
its tolerability [120]. The preliminary results of a phase-II 
double-blind trial with intravenous immunoglobulins against 
placebo in 24 AD patients for 6 months, showed better evo-
lution in clinical global impression (p < 0.001) but no sig-
nificant difference was reached regarding cognition (paper 
presented by N. Relkin et al. at the 60
th Annual Meeting of 
the American Academy of Neurology, April 2008).  
 Insulin  accelerates  A intracerebral circulation and 
elimination, and increases of the brain insulin resistance 
have been reported in many AD patients. Showing insulin 
resistance during midlife increases the risk of suffering AD 
in subsequent years [121]. For this reason, the effectiveness 
of rosiglitazone has been researched; it reduces such resis-
tance, is anti-inflammatory and stimulates mitochondrial 
biogenesis [122]. In a double-blind placebo-controlled trial 
(n=518) cognitive improvement was only observed in the 
group of patients without the APO E 4 allele [123] and, in 
another study in which 30 patients were followed up for 6 
months, those patients who received rosiglitazone did not 
show the diminution of A in cerebrospinal fluid shown by 
the placebo group [124]. It seems to be necessary to widen 
experimentation with this substance as well as to check to 
what extent it produces in AD patients the same cardiovascu-
lar events it causes in diabetes patients [125]. Intranasal in-
sulin has also been researched since it increases glucose 
availability in the brain, scarcely affecting its peripheral me-
tabolism. In a placebo-controlled study (n=25) treated pa-
tients showed better results regarding attention, memory and 
functional capacity [126]. As it occurs with rosiglitazone, it 
seems that the treatment is only effective in patients without 
the APO E 4 allele [127].  
 Curcumin, already mentioned in the previous section, 
binds to amyloid deposits and facilitates their elimination 
[112], although such action produced no significant clinical 
or serum A changes in a narrow trial [113].  
  Stimulation of plasminogen through tPA (tissue plasmi-
nogen activator) and the subsequent generation of plasmin 
reduces  A formation and accelerates its elimination. For 
this reason, the possible usefulness of a treatment with PAI-1 
(PAI = plasminogen activator inhibitor) or TGB-1 (PAI-1 
inductor) inhibitors or antagonists has been raised [128]. It 
has also been observed, however, that tPA induces the acti-
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neurotoxicity [129], so that the application of the above men-
tioned treatment may turn out to be risky.  
 Somatostatin  modulates  A-proteolysis mediated by ne-
prilysin. In AD, a somatostatin depletion facilitates A-
accumulation. Drugs analogous to somatostatin (e.g. octreo-
tide, ineffective in AD [130]), drugs which stimulate soma-
tostatin release (for instance FK962, ineffective in a phase-II 
study) or drugs that act on its receptors, have been consid-
ered as candidates for experimentation aimed at improving 
the evolution of AD [131, 132].  
II.D. Drugs to Reduce Neurofibrillary Degeneration  
  Phosphorylated tau-protein binds to microtubules in or-
der to facilitate their assembly, assuring the stability of the 
neural cytoskeleton. A correct phosphorylation requires a 
balance between the action of some kinases and phospha-
tases (especially GSK 3, cyclin-dependent protein kinase —
cdk5— and protein-phosphatase 2A —PP-2A—). GSK-3 
plays a more relevant role than GSK-3 in tau-phospho-
rylation, while the opposite occurs in APP processing to pro-
duce A. There is a GSK3 hypothesis of AD, according to 
which GSK-3 hyperactivity would be responsible for exces-
sive A-production, periplaque microglia reaction and tau-
hyperphosphorylation. The latter, in turn, alters axonal trans-
port, reduces the firmness of the cytoskeleton and induces 
the formation of neurofibrillary tangles [133]. An increase of 
endogenous inhibitors of PP-2A in AD has also been ob-
served [134]. From a therapeutic viewpoint, it may be possi-
ble to inhibit GSK-3 or stimulate PP-2A, having identified 
subgroups of AD that may respond differently to these 
treatments [135]. Molecules with anti-GSK3 properties have 
been investigated in antineoplastic research, some of them 
being suggested to be applied to AD, such as certain deriva-
tives of indirubin [136], paullones [137], aloisines [138] or 
hymenialdisine [139]. Lithium and valproic acid have also 
been studied as GSK-3 inhibitors [140]. Valproate does not 
act on cortical GSK-3 [141] and, regarding lithium, some 
researchers think that it acts on GSK-3 and GSK-3 and, 
due to its action on the latter, reduces A-production [142], 
while other researchers have observed A-increases, which 
they attribute to a mechanism not related to GSK3 [143].  
  Among the multifunctional drugs with anti-GSK3 action, 
the afore-mentioned lovastatin [82] and thiadiazolidinones 
can be cited. The latter have anti-inflammatory and neuro-
protective effect, partly because they activate nuclear perox-
isome proliferator-activated receptors (PPAR) and partly 
because they inhibit GSK-3 [144, 145].  
 Nicotinamide (vitamin B3) produces cognitive improve-
ment and phospho-tau reduction, mediated by its action on 
kinases, in transgenic mice (paper presented by KN Green et 
al. at the 60
th Annual Meeting of the American Academy of 
Neurology, April 2008). Therefore, it is a candidate mole-
cule to be valued in AD patients, maybe as a complement to 
other treatments.  
  On the other hand, memantine stimulates PP-2A, thus 
contributing to the reduction of neurofibrillary degeneration 
[39, 40].  
 Paclitaxel, which is related to taxol, stimulates tubulin 
polymerization and acts as a microtubule stabilizer [146].  
 Currently,  active immunotherapy with phosphorylated 
tau is under research. The generation of antibodies that re-
duce neurofibrillary tangles with no inflammatory reaction 
has been observed in animals [147].  
II.E. Drugs to Reduce Excitotoxicity and/or Oxidative 
Stress  
  Glutamate excess in synapses in diseased brain areas has 
deleterious effects for the cell (excitotoxicity). It causes ex-
cessive entrance of calcium into the cell, with an increase of 
the oxidative activity and functional damage to mitochon-
drias. LY451395, a modulator of glutamate AMPA receptors, 
did not reach significant clinical differences against placebo 
in a trial [148]. Dimebolin hydrochloride (Dimebon
®) is an 
acetyl and butyrylcholinesterase inhibitor that blocks the 
entrance of calcium through L-type (voltage-dependent) and 
NMDA (glutamatergic) channels, having symptomatic and 
neuroprotective effects [149, 150], and modulating mito-
chondrial membrane pores, so that it helps preserve mito-
chondrial function [151]. In a one-year-long double blind, 
placebo-controlled, phase-II study with 183 patients, signifi-
cant improvements in cognition, behavior and functional 
autonomy were observed [152]. Patients are currently being 
enrolled in a phase-III study (http://www.alzforum.org/ 
new/detail.asp?id=1590; http://www.medivation.com). Me-
mantine is the antagonist drug of NMDA receptors that has 
given us the greatest amount of results within the field of 
AD. The reduction of excitotoxicity and of oxidative damage 
is one of its main functions [153]. Its proven symptomatic 
effect [5-10] and the fact of reducing tau-
hyperphosphorylation [39, 40] make it an interesting drug 
with which to treat AD. Anyway, it will be necessary to 
prove its possible modifying effect in AD evolution through 
trials specifically designed for such aim. Other new-
generation anti-NMDAs such as neramexane are currently 
being researched for neuroprotection in AD [154]. No sig-
nificant differences were observed in a phase-III trial with 
415 patients in which double-blind comparisons were estab-
lished between a single anticholinesterase or a combination 
with neramexane; this research is ongoing with the admini-
stration of such drug as monotherapy against placebo.  
  Drugs with antioxidant action such as memoquin,  lipo-
crine,  colostrinin,  curcumin,  rosiglitazone,  clioquinol or 
PBT-2 have already been mentioned in previous sections due 
to their multifunctional capacity. Some epidemiological and 
prospective studies observe lower AD incidence or progres-
sion in individuals taking vitamin E, preferably in combina-
tion with vitamin C [155-157], but a Cochrane analysis does 
not find clear evidence of any beneficial effect [158]. Fur-
thermore, a meta-analysis showed an increase of mortality in 
individuals taking more than 150 UI/day of vitamin E [159]. 
Ginkgo biloba has antioxidant effects, but the most recent 
trials have failed to find any benefit on progression of cogni-
tive impairment or AD [160-162]. Furthermore, such treat-
ment is not free from a small risk of ischemic or hemor-
rhagic events [162, 163].  
 Melatonin has antioxidant and antiapoptotic properties, it 
increases mitochondrial energetic metabolism and reduces 
tau-hyperphosphorylation and A-formation and deposit 
[164, 165]. Moreover, its MT1 and MT2 receptors are al-
tered in AD [166]. Experimentation in AD animal models 
leads us to think of a favorable clinical effect of melatonin, 
but no controlled extensive clinical trial have been carried 
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ify AD incidence or progression. Likewise, tacrine-
melatonin hybrid molecules, which presumably would add 
the symptomatic effect of the anticholinesterase to the com-
bination, are currently under research [167].  
  Studies developed with selegiline, an IMAO- with anti-
oxidant properties, conclude that there is no justification to 
use it in AD patients [168]. Rasagiline has different aspects 
from selegiline that make it more attractive, apart from fa-
cilitating APP non-amyloidogenic processing [169]. AD 
research, however, seems to have moved towards a bifunc-
tional molecule, ladostigil, that combines properties of rivas-
tigmine and rasagiline [169, 170].  
  Higher cortisolemia and greater cortisol/DHEA (DHEA 
= dehydroepiandrosterone, antiglucocorticoid) ratio are ob-
served in the plasma of some AD patients than in healthy 
individuals of the same age [171], which may facilitate cog-
nitive impairment and hippocampal atrophy [172]. For this 
reason, DHEA has been considered as a potential treatment 
of AD, since it reduces excitotoxicity and has antioxidant 
properties [173, 174]. In a narrow double-blind placebo-
controlled study of DHEA, no significant differences were 
observed either in cognitive performance or in clinical global 
impression [175].  
 Huperzine  A, an alkaloid of the herb huperzia serrata 
used in Chinese traditional medicine, has antioxidant proper-
ties, is an ACEI, stimulates muscarinic and neuronal growth 
factor receptors, increases APP non-amyloidogenic process-
ing, protects against apoptosis and cytotoxicity caused by 
A, glutamate or ischemia. In clinical trials carried out in 
China, it has been observed that it produces memory im-
provement in elderly people with amnesic disorder and in 
AD patients or those with vascular dementia, probably due to 
its ACEI action [176]. It would be desirable to see if its neu-
roprotective effects lead to favorable modifications in AD 
evolution. It is currently under a phase-II trial in USA.  
  A technique to increase the efficacy of already existing 
treatments is dimmer’s synthesis. Among them we can men-
tion  bis-tacrine (tacrine dimmer) and bis-HupA or 
bis-hupyridone (dimmer of a fraction of huperzine A). Bis-
tacrine also has BACE-1 inhibitory action and blocks 
NMDA receptors, that provides it with an additional neuro-
protective action [177]. 
  Polyunsaturated fatty acids facilitate neuroplasticity in 
neuronal membranes and synaptic transmission, have anti-
oxidant and antiapoptotic properties, protect against excito-
toxicity, inhibit the production of proinflammatory cytokines 
and, furthermore, reduce A and phospho-tau production 
while improving learning capacity [178-182]. These fatty 
acids are not synthesized in the brain but come from food. In 
animal models and in humans it has been observed that diets 
rich in these substances or containing a supplement of them 
(omega-3 fatty acids, docosahexaenoic acid) reduce AD risk, 
especially in individuals who do not carry the Apo E 4 al-
lele [183, 184], though some researchers have obtained nega-
tive results [185]. These products are available in the market 
as nutritional supplement. In a small group of AD patients a 
significantly favorable effect was observed in cognition 
(MMSE) from treatment with omega-3 fatty acids plus lipoic 
acid –antioxidant- (paper presented by L. Shinto et al. at the 
60
th Annual Meeting of the American Academy of Neurol-
ogy, April 2008).  
 Propentofylline is a xanthinic derivative which inhibits 
adenosine reuptake and phosphodiesterase. Among other 
actions, it reduces the production of free radicals and micro-
glia activation, stimulates the synthesis and release of the 
nerve growth factor, facilitates APP non-amyloidogenic 
processing and decreases activated GSK-3 [186]. The re-
sults from phase-II and III trials point out that improvement 
in cognition, global function and functional autonomy is 
achieved and the follow-up of individuals who left the study 
seems to indicate that propentofylline slows down AD pro-
gression [187, 188]. In a phase-II study it was observed that 
brain metabolism (PET) increased after stimulation with a 
verbal task [189]. However, the authors of the Cochrane 
analysis point out that part of the data obtained through ex-
perimentation has not been published by the researchers and 
that much of the published data does not discriminate be-
tween different etiological types of dementia [188]. The re-
search of this drug in relation to AD has been interrupted.  
II.F. Cell Therapy, Regenerative Medicine  
  The incorporation of multipotential cells into the brain to 
stimulate neurogenesis in brain areas affected by AD (cell 
therapy) is a promising field. In animal models, implanted 
cells undergo intracerebral migration, differentiate them-
selves and improve memory [190]. For multiple reasons, the 
treatment is complex. The optimum source of stem cells that 
should be implanted is a question currently under public and 
scientific debate. The implantation technique needs to mini-
mize risks. The implanted cells should not only survive but 
they also need proliferate, differentiate themselves by acquir-
ing the specialization of affected cells and, finally, integrate 
themselves in complex cell networks in order to make their 
function operative. The use of out-of-patient multipotential 
cells (obtained from embryonic tissues, bone marrow, um-
bilical cord or placenta, for example) may induce rejection 
more easily than using the patient’s own cells. In this sense, 
nerve cells have already been obtained from the patient’s 
skin or bone marrow [191]. Embryonic stem cells have great 
replication capacity but they also present a great risk for de-
veloping tumors [192]. An alternative consists of activating 
(through genetic modifications or nerve growth factors) stem 
cells which are inactive whether in the own brain or in an-
other part of the body [191, 193, 194]. Moreover, this proce-
dure avoids the surgery required to implant exogenous cells. 
A recent trial showed that stem cells administered intrave-
nously to transgenic mice cross well the blood-brain barrier; 
this might solve the problems associated with implantation 
surgery [195]. On the other hand, if there is an excess of 
APP in the brain, multipotential cells become glial cells to a 
greater extent than neuronal cells (thus producing gliosis), so 
that it would be necessary to modulate the presence of APP. 
A variant of phenserine has been tested with such aim [196, 
197]. Interesting to note is the study in which 6 AD patients 
were followed up for 22 months after being implanted ge-
netically-modified autologous skin fibroblasts in order to 
produce human nerve growth factor. The results range from 
a slower progression of cognitive impairment to an increase 
of cerebral cortical activity (PET) [198].  
  Many of us, who are engaged in neurological clinical 
practice and are mere observers of this matter, suspect that 
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a)  AD affects extensive associative and limbic areas of 
the brain as well as multiple subcortical gray-matter 
nuclei, which are the source of several neurotransmit-
ters. Therefore, treatment with stem cells should act 
on various points and new cells should acquire varied 
specializations.  
b)  When associative areas formed by axon and dendrite 
tangles of varied origin are affected, it seems difficult 
for newly arrived cells to properly integrate their new 
tentacles (both structurally and functionally) in such 
complex networks.  
c)  Stem cells which begin to specialize within the dis-
eased brain will have to do it in a hostile environ-
ment. When the first symptoms appear, several altera-
tions —which include the activation of microglia and 
other inflammatory elements, accumulation of neuro-
excitatory aminoacids, deposit of proteins with neuro-
toxic effects, etc.— have already been taking place in 
the brain for many years and many surviving cells are 
also functionally damaged, all of which hinders the 
development of implanted cells.  
  In short, it seems more feasible to introduce cells into the 
brain intending to stimulate the production of neuronal 
growth factors or the secretion of deficient neurotransmitters, 
instead of cells that attempt to substitute degenerated brain 
tissue.  
  On the other hand, knowing the possibility of creating 
transgenic mice, we may attempt to correct mutations and 
polymorphisms that cause the disease or increase the risk to 
suffer from it. This genetic manipulation is very difficult to 
apply in sporadic AD, since there are many genetic risk ele-
ments (many of which are still unknown) and difficulties of 
an ethical nature will be found in monogenic hereditary 
forms. In any case, what today seems to be utopian may be-
come a pleasant reality within the not-too-distant future. 
However, the path currently followed by cell therapy and 
genetic manipulation and engineering to treat degenerative 
dementia may prove to be both thorny and lengthy.  
REFLECTIONS ON THE DIFFICULTIES TO   
DEVELOP TREATMENTS THAT MODIFY THE 
EVOLUTION OF THE ALZHEIMER’S DISEASE  
  Historically, in 1976 the loss of cerebral cholinergic neu-
rons in AD had already been detected [199], in 1979 an 
ACEI (physostigmine) had been tested [200, 201], in 1981 
we knew the results of a study with tacrine [202] and in 1993 
the same drug was approved by the FDA as a symptomatic 
treatment for AD. Technological and communication ad-
vances made us believe that the time intervals for approving 
new treatments would become progressively shorter. How-
ever, research on drugs which modify the course of the dis-
ease is considerably different from that which searches for 
symptomatic medication. For instance, in 1991 the relation 
between secretases and A-synthesis was already known 
[203]. In 1999 it was established that presenilins are -
secretases [204] and the characteristics of BACE (-
secretase) were detailed [205]. A year later the race had al-
ready begun to synthesize secretase inhibitors to treat AD. 
Unlike previous predictions it might have been foreseen, in 
2008 there is still a long way to go to ready these molecules 
for market, if they do finally demonstrate their efficacy. As 
the first decade of the new century is coming to an end, none 
of the treatments aimed at modifying AD progression seems 
to be at the point of imminent approval, despite the hundreds 
of molecules now in different research stages, some of which 
are presented as effective in international meetings and con-
gresses. What reasons can we give for our present situation?  
  Research on drugs that are directed toward brain neu-
rotrophism, neuroprotection or neuroplasticity in AD pa-
tients, and that try to significantly reduce the progression of 
its preclinical process or clinical course, differs from the 
research that is necessary to prove the symptomatic effect of 
a drug [22]. Some difficulties are shared by all therapeutic 
research such as the possibility that effectiveness and toler-
ability (theoretically foreseeable or even observed in trials 
with animals) are not evident when experimenting with hu-
mans. When investigating drugs that modify the evolution of 
AD other difficulties are to be expected (Table 4).  
  When the first symptoms appear in AD patients, the un-
derlying neuropathological process has been brewing for 
decades [206]. If a drug could stop or slow down the 
physiopathological phenomena that provoke cell dysfunction 
and death in certain parts of the brain, it should be applied in 
preclinical stage with the aim of avoiding or delaying the 
symptom's appearance. Since AD is a disease that mainly 
appears at advanced ages, when mortality due to other causes 
is already very present, an extension of the preclinical stage 
would mean that many patients would not even show the 
first symptoms and some others would not go beyond the 
stage of mild cognitive impairment. That is, prevalence of 
dementia due to AD would be reduced. However, carrying 
out research on humans in the preclinical stage turns out to 
be extremely difficult. If we exclude known and asympto-
Table 4.  Difficulties for the Development of Drugs that Modify the Evolution of AD 
 
•  Scarcity of AD markers in preclinical stage  
•  Scarcity of markers of AD phenotypes  
•  Difficulty to obtain molecules with selective action on diseased cells  
•  Most drugs will have weak effects since they act only on a part of the etiopathogenic chain  
•  It is necessary to distinguish between symptomatic action and changes in the course of the disease  
•  Need of a prolonged period of observation to prove delay in progression  
•  Need to work with very wide human samples to achieve clinical evidence and statistical signification  
•  High economic cost of trials designed to ascertain modifications in AD evolution  38     The Open Neurology Journal, 2009, Volume 3  Alfredo Robles 
matic carriers of a mutation producing familial AD, we do 
not have available suitable preclinical markers for the rest of 
the population. Besides, on the assumption that research took 
place in this group of pre-patients, the results could only be 
evaluated by observing the progression of histopathological 
lesions, since no clinical or biochemical markers -useful to 
create a base to see the effectiveness of the researched drug- 
are known in such preclinical stages. Even if we assume that 
changes in the concentration of lesions are found (for in-
stance, by using PET with specific markers such as Pitts-
burgh Compound B –PIB-) there would be little certainty 
that molecular and cellular pathology had been really de-
layed. It can be possible that A-oligomers be harmful and 
plaques only constitute residues of an already-finished 
pathological phenomenon, so that a drug might reduce the 
concentration of amyloid plaques without obtaining any fa-
vorable clinical result.  
  When dementia is present it is less difficult to identify 
patients with probable AD. Neuropsychological markers, 
phospho-tau and A42 alterations in cephalospinal fluid, hy-
poactivity of posterior cingulum extendable to other associa-
tive temporoparietal areas (through PET or SPECT) and no-
ticeable atrophy in hippocampal regions (through magnetic 
resonance) allow practitioners to diagnose AD with high 
reliability, at least in typical cases without other alterations 
associated to it. However, AD is a heterogeneous disease. 
The genes that cause or facilitate its development are varied 
(Table 2) and, maybe for this reason, varied phenotypes are 
found in practice (frontal variant of AD, posterior cortical 
atrophy, AD starting with progressive aphasia or apraxia, 
AD with Lewy bodies). It is possible that, when researching 
drugs aimed at interfering in AD pathogenic sequence, it is 
valuable to know the patient’s phenotype supposing that, due 
to the disease’s heterogeneity, the effectiveness of the drug 
may differ within each subtype. Thus, it would be advisable 
to investigate within homogeneous, well-characterized 
groups. Regarding this aspect, we find lack of criteria and 
markers that identify AD phenotypes in a reliable way and, 
furthermore, we do not know in detail the existing differ-
ences among them at molecular and cellular level. If we ac-
cept simple clinical selection of phenotypes, the fact of 
working with subgroups would increase the difficulty of 
reaching sufficient sample sizes, which should be quite large 
in this kind of research, as it will be commented on later.  
  If drugs act by interfering in the activities of the diseased 
cells, in many cases they generate adverse effects, because 
they may also interfere with the activities of healthy cells or 
because they may bear unnecessary actions for the treatment 
of the disease. Such is the case of many gamma-secretase 
inhibitors, which not only reduce APP hydrolysis but also 
that of many other substrates, thus producing undesirable 
side effects. Another example can be found in memantine; 
due to its voltage-dependent and fast blocking-unblocking 
mechanism of action, it does not have problems related to 
tolerability, while other NMDA receptor antagonists previ-
ously researched (dizocilpine, phencyclidine, ketamine) pro-
duced severe adverse effects since they block these receptors 
in a more indiscriminate and permanent manner [4, 207]. 
Therefore, drugs characterized by high selectivity should be 
created in order to act only on something that works badly 
and only in ill cells. This process of increasing selectivity is 
time consuming and delays the availability of effective and 
well-tolerated drugs.  
  The expected effect of new treatments is the reduction of 
disease progression, although in many cases symptomatic 
improvement takes place simultaneously. In these situations, 
it is necessary to distinguish between both effects in order to 
demonstrate that the treatment modifies disease evolution. 
Techniques available for such an aim were described in a 
previous section of this article. Finding a difference becomes 
progressively more difficult as less time is available for ob-
servation. Regarding modification of disease course, there 
should be found not only statistical differences against pla-
cebo regarding clinical parameters, but also evidence of a 
measurable slowing effect (for instance, prolongation of the 
duration of dementia stages or the time of survival).  
  A low effectiveness of these drugs is possible, as they do 
not act on the whole etiopathogenic sequence, which means 
that it is going to be difficult to prove significant differences 
against patients who do not follow this treatment. If a drug 
were highly effective, it might be sufficient to show that the 
progression slope (throughout a period probably no shorter 
than 18 months) is significantly lower than that observed in 
Table 5.  Selection of Treatments Investigated to Modify the Course of AD. Multifunctional Drugs can be Found in More than One 
Section 
 
Action  
They reduce A production   atorvastatin*
a, bis-tacrine, cerebrolysine*, fenretinide, flurbiprofen*, GSK 188909, huperzine A
a, ibuprofen*
b, 
ladostigil, leuprorelin*
b, LY450139
b, memoquin, imatinib*, neuropeptide PACAP, simvastatin*
b 
They inhibit A aggregation   AZD-103, -sheet-brakers, colostrinin, curcumin, lipocrine, memoquin, PBT-2
a, tramiprosate 
They enhance A elimination   PAI-1 or TGB-1 antagonists, curcumin, active immunotherapy (ACC-001, CAD-106), passive immunother-
apy (bapineuzumab
b), intranasal insulin, rosiglitazone*
b 
They reduce neurofibrillary degeneration   aloisines, indirubin derivatives, hymenialdisine, anti-phospho- immunotherapy, lithium*, lovastatin*, meman-
tine*, memoquin, nicotinamide*, paullones, thiadiazolidinones 
They decrease excitotoxicity and oxida-
tive stress  
docosahexaenoic acid*
b, 3 fatty acids* + lipoic acid*, bis-tacrine, colostrinin, curcumin, dihydroepiandroster-
one*, dimebon
b, tacrine-melatonin hybrids, huperzine A
a, ladostigil, lipocrine, melatonin*, memantine*, 
memoquin, neramexane
b, PBT-2
a, rosiglitazone*
b, vitamins E+C*  
PAI = plasminogen activator inhibitor. TGB: transforming grow factor.  
*: Currently marketed.  
In phase-II (a) or phase-III (b) research, according to http://www.alzforum.org/drg/drc/default.asp [13.Nov.2008].  New Treatments for Alzheimer Disease  The Open Neurology Journal, 2009, Volume 3    39 
the control group [19, 21]. However, in most cases it is prob-
able that, in order to prove effectiveness, it is necessary to 
test the drug during several years in a large number of pa-
tients (several thousands of them, if we keep in mind the 
need to reach evidence as quickly as possible, obtaining 
non-intense benefit, and that a progressive loss of individuals 
is foreseeable throughout the follow-up process). The conse-
quence of these requirements is a high cost that few compa-
nies are capable of assuming.  
  In order to lessen difficulties related to the scarce effec-
tiveness of these drugs, the following strategies have been 
conceived:  
a) Searching  for  drugs which act on items close to the 
origin of the pathogenic cascade (e. g., - or -
secretase inhibitors), expecting to achieve greater ef-
fectiveness than that obtained with those which coun-
teract an intermediate or final element of such a se-
quence (e. g., antioxidant substances or drugs which 
help eliminate amyloid plaques).  
b)  Synthesizing products active in several aspects of 
pathogeny (examples shown in Table 5).  
c)  Creating drugs with both neuroprotective and symp-
tomatic effects (Table 1). 
d)  Testing the effectiveness of cocktails of presumably-
complementary substances. This option would turn 
out to be operatively more feasible if commercialized 
drugs, with already contrasted tolerability (see Table 
5), were associated to one of the new molecules that 
have shown good tolerability and results, although not 
good enough for its approval.  
  In another sense, the incorporation of pharmacogenomics 
into clinical practice within the next years is foreseeable. It 
may not be very useful in discovery new treatments, but it 
may help optimize the use of available drugs. Certain geno-
types or polymorphisms condition qualitative aspects of the 
drugs’ target molecules or aspects related to their metabo-
lism or other elements of the pathogenic chain, so that know-
ing them allows identifying subgroups of responders and/or 
non-responders in a certain treatment, or indicating those 
with good or bad tolerability. Let us consider some exam-
ples:  
•  Carriers of polymorphism rs733722 of the gene 
which codifies ChAT (choline-acetyltransferase) 
show greater response to treatment with ACEI [208].  
•  Patients whose GST gene (glutathione-S-transferase 
encoder) does not produce M1 or T1 isozymes suffer 
greater risk to develop hepatotoxicity if they take 
tacrine [209].  
•  Genotype CYP2D6 influences the plasmatic concen-
tration and the effectiveness of donepezil [210]  
•  Patients without the K allele in the butyrylcho-
linesterase gene show greater response and less ad-
verse effects when treated with rivastigmine [211].  
•  Certain alleles of pro-inflammatory genes may detect 
AD patients suitable to be treated with anti-
inflammatories [212]. 
•  Certain changes in the presenilin-1 encoding gene 
modify the antiamyloidogenic effect of 
anti-inflammatories. Mutations in exon-9 of PSEN1- 
remarkably reduce the efficacy of NSAIDs, while 
PSEN1-M146L and APP-V717F mutations increase 
their effect [213, 214].  
•  The PS1-L166P mutation induces ineffectiveness of 
LY-411575 (-secretase inhibitor) [214].  
•  In a study with rosiglitazone, favorable results were 
only achieved in patients without the allele APO E 4 
[123].  
  In summary, the race to develop treatments that modify 
the evolution of AD has obstacles and may produce a general 
impression of slowness, but it is unstoppable. The efforts 
carried out in order to solve the difficulties are huge and 
highly expensive, but they are not going to be in vain. Any 
drug that slows down the progression of AD will immedi-
ately have favorable repercussions on the disease’s preva-
lence and, in an ageing world, it will mean a great step in 
improving the prospects of health and wellbeing.  
ABBREVIATIONS 
ACEI =  Acetylcholinesterase  inhibitors 
AD =  Alzheimer’s  disease 
APP  =  Amyloid precursor protein 
A =  Beta-amyloid 
BACE =  -site APP cleaving enzyme 
DHEA =  Dihydroepiandrosterone 
FDA  =  Food and Drug Administration 
GSK =  Glycogen  synthase  kinase 
I-BACE = BACE  inhibitors 
MMSE  =  Folstein minimental state examination 
NSAID = Non-steroidal  anti-inflammatory  drugs 
PET =  Positron  emission  tomography 
PP-2A =  Protein-phosphatase  2A 
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